- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
| Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
|---|
Multiple Targets and Therapeutic Areas
| . | . |
Partner: 
Collaborative program: Astex Pharmaceuticals and GlaxoSmithKline entered into a collaboration agreement to discover, develop and commercialize novel compounds directed against multiple therapeutic targets of interest to GSK in November 2009.
Under the collaboration, Astex applied its fragment chemistry platform, Pyramid™, to multiple targets identified by GSK, with the objective of identifying and developing new candidate drugs. The targets were selected from multiple therapeutic areas within GSK. GSK are progressing potential drug candidates derived from the collaboration; the most advanced has entered a Phase 1 clinical trial.